DexCom, Inc. (NASDAQ:DXCM) Receives Average Recommendation of “Buy” from Analysts

Shares of DexCom, Inc. (NASDAQ:DXCMGet Rating) have been assigned an average rating of “Buy” from the twenty-one ratings firms that are currently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and fifteen have assigned a buy rating to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $565.33.

A number of equities analysts recently commented on the company. Guggenheim upgraded DexCom from a “neutral” rating to a “buy” rating and set a $580.00 price objective on the stock in a research report on Friday, January 7th. Bank of America started coverage on DexCom in a research report on Wednesday, March 2nd. They set a “buy” rating on the stock. Raymond James reduced their target price on DexCom from $618.00 to $538.00 and set an “outperform” rating on the stock in a research report on Wednesday, January 19th. Robert W. Baird reduced their target price on DexCom from $625.00 to $560.00 in a research report on Friday, February 11th. Finally, Morgan Stanley reduced their target price on DexCom from $570.00 to $514.00 and set an “equal weight” rating on the stock in a research report on Friday, February 11th.

In related news, CEO Kevin R. Sayer sold 22,674 shares of the business’s stock in a transaction on Tuesday, January 18th. The stock was sold at an average price of $435.56, for a total transaction of $9,875,887.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Steven Robert Pacelli sold 250 shares of the business’s stock in a transaction on Monday, January 24th. The stock was sold at an average price of $416.77, for a total value of $104,192.50. The disclosure for this sale can be found here. Insiders sold 33,572 shares of company stock valued at $14,705,577 over the last ninety days. Insiders own 0.52% of the company’s stock.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Rise Advisors LLC acquired a new position in shares of DexCom during the 4th quarter worth about $26,000. Equitec Proprietary Markets LLC acquired a new position in shares of DexCom during the 4th quarter worth about $29,000. MUFG Americas Holdings Corp acquired a new position in shares of DexCom during the 3rd quarter worth about $36,000. Benjamin F. Edwards & Company Inc. acquired a new position in shares of DexCom during the 4th quarter worth about $37,000. Finally, American National Bank acquired a new position in shares of DexCom during the 4th quarter worth about $37,000. 95.14% of the stock is owned by hedge funds and other institutional investors.

Shares of DexCom stock opened at $498.80 on Thursday. DexCom has a one year low of $318.45 and a one year high of $659.45. The company has a market cap of $48.58 billion, a price-to-earnings ratio of 321.81, a PEG ratio of 8.50 and a beta of 0.94. The company has a debt-to-equity ratio of 0.76, a quick ratio of 4.62 and a current ratio of 5.11. The business’s 50 day moving average price is $445.54 and its 200 day moving average price is $507.91.

DexCom’s stock is set to split before the market opens on Friday, June 10th. The 4-1 split was announced on Friday, March 25th. The newly issued shares will be payable to shareholders after the closing bell on Thursday, June 9th.

DexCom (NASDAQ:DXCMGet Rating) last announced its quarterly earnings data on Thursday, February 10th. The medical device company reported $0.68 EPS for the quarter, missing the Zacks’ consensus estimate of $0.86 by ($0.18). DexCom had a return on equity of 12.87% and a net margin of 6.32%. The company had revenue of $698.20 million for the quarter, compared to analysts’ expectations of $698.66 million. During the same quarter in the previous year, the business posted $0.91 EPS. The business’s quarterly revenue was up 22.7% compared to the same quarter last year. On average, analysts predict that DexCom will post 3.39 EPS for the current fiscal year.

About DexCom (Get Rating)

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system.

Featured Articles

Analyst Recommendations for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.